<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378739</url>
  </required_header>
  <id_info>
    <org_study_id>172870</org_study_id>
    <nct_id>NCT03378739</nct_id>
  </id_info>
  <brief_title>Inova Cardiogenic Shock Registry (INOVA SHOCK)</brief_title>
  <acronym>INOVASHOCK</acronym>
  <official_title>Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect retrospective clinical outcomes related to acute decompensated heart failure
      cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus
      historical survival rates.

      To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after
      initiation of the Cardiogenic Shock team on January 1, 2017.

      To collect outcomes related to implementation of mechanical circulatory support versus no
      circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO)
      versus intracorporeal axial-flow (Impella).

      â€¢ Assess survival at three time points.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any patient with cardiogenic shock, whether inpatient or transferred from another facility,
      treated at the Inova Heart and Vascular Institute shall be included in this registry. This
      includes adults with and without decision making capacity over the age of 18 years old.

      The primary investigator (PI) will designate the data points to be included in the database
      in order to assess the efficiency of procedures and protocols in the treatment of cardiogenic
      shock at the IHVI as administered by the Shock team, to identify relationships between
      treatment and negative morbidity and mortality outcomes, and to monitor and improve quality
      of care delivered.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">May 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Retrospective review of Cardiogenic shock patients outcomes</measure>
    <time_frame>1 Year</time_frame>
    <description>To create an archive of retrospective clinical outcomes (acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock) and compare current versus historical survival rates.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Cardiogenic Shock</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiogenic Shock team activation</intervention_name>
    <description>Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at the IHVI with documented Cardiogenic Shock team intervention for acute
        decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic
        shock
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Patients at the IHVI with documented Cardiogenic Shock team intervention for acute
        decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic
        shock.

        Exclusion Criteria:

        -Patients under the age of 18 will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexander Truesdell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Health Care Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Garofalo, BSN</last_name>
    <phone>703-776-7702</phone>
    <phone_ext>2018</phone_ext>
    <email>Stephanie.Garofalo@inova.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Saulino, RN BSN MPA</last_name>
    <phone>703-776-4711</phone>
    <email>patricia.saulino@inova.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Saulino, MSN</last_name>
      <phone>703-786-5987</phone>
      <email>Patricia.Saulino@inova.org</email>
    </contact>
    <investigator>
      <last_name>Alex Truesdell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benham Tehrani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inova Health Care Services</investigator_affiliation>
    <investigator_full_name>Alexander G. Truesdell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cardiogenic</keyword>
  <keyword>shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>To facilitate both national and international research efforts in cardiogenic shock patient's collaborative studies may occur with other institutions outside of Inova.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

